Why Aridis Pharmaceuticals Shares Are Soaring Today
Why Aridis Pharmaceuticals Shares Are Soaring Today
為什麼阿里迪斯製藥股票今天飆升
- Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections.
- The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol and was conducted with funding support from the Cystic Fibrosis Foundation.
- AR-501 is being developed as a once-per-week inhaled dosing regimen self-administered using a commercially available nebulizer device.
- Also Read: Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action.
- The study's primary and secondary safety and pharmacokinetics (PK) endpoints were met.
- Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated. No drug-related serious adverse events (SAEs) were observed.
- The majority of treatment-emergent adverse events (TEAEs) were respiratory in nature and primarily mild to moderate in severity.
- CF patients achieved high uptake of AR-501 in the respiratory tract, as measured by sputum concentrations, at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa
- Inhaled delivery achieved more than 10-fold higher respiratory uptake of gallium (AR-501) than past clinical studies of intravenous (IV) gallium, resulting in lung function improvement and P. aeruginosa reduction.
- Price Action: ARDS shares are up 47.70% at $0.68 during the premarket session on the last check Monday.
- Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections.
- The study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol and was conducted with funding support from the Cystic Fibrosis Foundation.
- AR-501 is being developed as a once-per-week inhaled dosing regimen self-administered using a commercially available nebulizer device.
- Also Read: Aridis' Inhaled Pan-Coronavirus Antibody Cocktail Shows Encouraging Preclinical Action.
- The study's primary and secondary safety and pharmacokinetics (PK) endpoints were met.
- Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated. No drug-related serious adverse events (SAEs) were observed.
- The majority of treatment-emergent adverse events (TEAEs) were respiratory in nature and primarily mild to moderate in severity.
- CF patients achieved high uptake of AR-501 in the respiratory tract, as measured by sputum concentrations, at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa
- Inhaled delivery achieved more than 10-fold higher respiratory uptake of gallium (AR-501) than past clinical studies of intravenous (IV) gallium, resulting in lung function improvement and P. aeruginosa reduction.
- Price Action: ARDS shares are up 47.70% at $0.68 during the premarket session on the last check Monday.
- 阿里迪斯制药公司 （NASDAQ：ARDS）宣布了 AR-501 在囊性纖維化（CF）確診的綠草假單胞菌和其他潛在感染患者中對的 2a 期研究的初步頂線結果。
- 該研究評估了作為吸入氣溶膠施用的三種上升劑量 AR-501 的安全性和藥代動力學，並在囊性纖維化基金會的資金支持下進行的。
- AR-501 正在開發為每週一次的吸入劑量方案，使用市售的霧化器設備自我管理。
- 另請閱讀： Aridis' 吸入泛冠狀病毒抗體雞尾酒顯示令人鼓舞的臨床前行動。
- 該研究的主要和次級安全性和藥代動力學（PK）終點得到了滿足。
- 三個每週吸入劑量的 AR-501 在 6.4 毫克, 20 毫克, 和 40 毫克劑量水準的耐受性良好.沒有觀察到與藥物有關的嚴重不良事件。
- 治療出現的不良事件（TEAE）大多數都是呼吸道性質，嚴重程度主要是輕度至中度。
- CF 患者實現了高吸收 AR-501 在呼吸道, 作為由痰濃度測量, 在超過 50 倍以上的目標細菌的抑制所需的水平. 青草.
- 與過去對靜脈注射（IV）鎵的臨床研究相比，吸入分娩實現了鎵（AR-501）的呼吸吸收量高 10 倍以上，從而導致肺功能改善和綠草 P 減少。
- 價格行動： 在星期一上次檢查的盤前交易時段，ARDS 股票上漲了 47.70%，價格為 0.68 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧
點擊這裡與好友分享
暫無評論，快來留言吧！